Hemorrhagic disease of newborn
Reading File
Now let me search the medical library and PubMed in parallel for comprehensive coverage.
Finding Sources
Finding Sources
Searching PubMed
"hemorrhagic disease of the newborn" OR "vitamin K deficiency bleeding" newborn
Good. Now let me read the most relevant textbook sections in parallel.
Reading File
Reading File
Reading File
Reading File
Now let me search for more detailed clinical content on the types/classification and management.
Finding Sources
Finding Sources
Excellent - Tintinalli's has a dedicated section. Let me read that in detail.
Reading File
Reading File
Let me read the rest of the Tintinalli section on treatment, and also search for the Lippincott biochemistry section on vitamin K mechanism.
Reading File
Reading File
Let me now read the complete Tintinalli VKDB section more carefully (it seems the treatment part got cut off).
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Hemorrhagic Disease of the Newborn (HDN) / Vitamin K Deficiency Bleeding (VKDB)
Definition and Nomenclature
Hemorrhagic disease of the newborn (HDN) is a neonatal bleeding coagulopathy caused by a transitory deficiency of vitamin K-dependent clotting factors. The modern preferred term is vitamin K deficiency bleeding (VKDB), as the underlying mechanism is specifically vitamin K deficiency rather than a general hemorrhagic condition. - Tintinalli's Emergency Medicine
Pathophysiology
Vitamin K-Dependent Clotting Factors
Vitamin K is required for the gamma-carboxylation of glutamic acid residues on clotting factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S. Without this carboxylation, these factors cannot bind calcium ions and are functionally inert (called PIVKA - Proteins Induced by Vitamin K Absence or Antagonism). PIVKA-II (undercarboxylated, non-functional prothrombin) is elevated in vitamin K deficiency and is a confirmatory marker. - Tietz Textbook of Laboratory Medicine
Why Newborns are Deficient
Neonates are uniquely vulnerable due to a combination of factors:
| Factor | Explanation |
|---|---|
| Poor placental transfer | Vitamin K crosses the placenta poorly |
| Sterile gut at birth | No intestinal bacteria to synthesize vitamin K (menaquinones) initially |
| Low liver stores | Hepatic vitamin K stores are minimal at birth |
| Breast milk | Human milk provides only ~1/5 of the daily vitamin K requirement; cow's milk formulas are supplemented |
| Short half-life | Vitamin K has a short metabolic half-life |
Measurements of non-gamma-carboxylated prothrombin suggest vitamin K deficiency occurs in about 3% of live births without prophylaxis. - Goodman & Gilman's Pharmacological Basis of Therapeutics
Classification: Three Forms
| Form | Onset | Characteristic Features | Risk Factors |
|---|---|---|---|
| Early | Within 24 hours of birth | Cephalhematoma, intracranial hemorrhage, intrathoracic/intraabdominal bleeding | Maternal drugs (warfarin, phenytoin, isoniazid, rifampicin, cephalosporins) |
| Classic | Days 2-14 (2nd to 7th day most common) | Umbilical bleeding, circumcision site oozing, GI bleeding, ecchymoses | Breastfeeding, inadequate vitamin K stores |
| Late | 2-12 weeks (up to 6 months) | Often intracranial hemorrhage (most dangerous) | Exclusively breastfed, malabsorption, hepatobiliary disease, absent/refused prophylaxis |
Classic HDN usually presents in the first postnatal week. Late VKDB occurs from 2 to 24 weeks and has been most frequently attributed to inadequate or absent vitamin K prophylaxis. - Tietz Textbook of Laboratory Medicine
Clinical Presentation
Bleeding manifestations range from mild to life-threatening:
- Mild: Oozing from the umbilical stump, circumcision site, venipuncture sites, ecchymoses
- Moderate: Gastrointestinal bleeding (melena, hematemesis), cephalhematoma
- Severe/Life-threatening: Pulmonary hemorrhage, intracranial hemorrhage (ICH)
In developed countries with prophylaxis programs, 30%-60% of reported VKDB cases are associated with intracranial hemorrhage - a key reason for aggressive prophylaxis. - Tintinalli's Emergency Medicine
Risk Factors
- Breastfeeding (low vitamin K in human milk)
- Malabsorption or hepatobiliary disorders (cholestasis impairs fat-soluble vitamin absorption)
- Maternal medications: phenytoin, isoniazid, warfarin, anticonvulsants, certain cephalosporins (e.g., cefamandole)
- Lack of vitamin K prophylaxis at birth
- Home delivery without administration of vitamin K
- Countries with limited healthcare access
Laboratory Findings
- Prolonged PT (prothrombin time) - reflects deficiency of factors II, VII, X
- Prolonged aPTT (activated partial thromboplastin time) - reflects deficiency of factors II, IX, X
- Normal thrombin time (TT) and normal fibrinogen - distinguishes VKDB from DIC
- Normal platelet count
- Decreased hematocrit (proportional to blood loss)
- Elevated PIVKA-II (confirmatory marker)
- Measuring multiple vitamin K-dependent factors (vs. non-vitamin K-dependent factors) confirms the diagnosis
Diagnosis
- Clinical presentation in appropriate context (neonatal age, breastfed, no prophylaxis)
- Coagulation profile as above
- Response to vitamin K administration: factor levels normalize within ~6 hours; this therapeutic response is both diagnostic and curative
- PIVKA-II measurement if diagnosis uncertain
Treatment
Acute Treatment
| Scenario | Treatment |
|---|---|
| Active bleeding (any severity) | Immediate 1 mg vitamin K (phytonadione) SC, IM, or IV |
| Life-threatening hemorrhage | FFP 10-20 mL/kg + vitamin K (do not wait for labs if ICH suspected) |
| Severe hemorrhage (INR not quickly reversible) | Prothrombin complex concentrate (PCC) as adjunct |
- IM route: Risk of significant hematoma at injection site
- IV route: Risk of anaphylactoid reaction (give slowly)
- The IV route corrects coagulation within about 6 hours
Do not wait for laboratory results if clinical suspicion of intracranial bleeding is high. - Tintinalli's Emergency Medicine
If the mother received warfarin or anticonvulsants, the dose may need to be increased or repeated. Some clinicians treat mothers on anticonvulsants with oral vitamin K 20 mg/day for 2 weeks before delivery. - Goodman & Gilman's
Prophylaxis
The American Academy of Pediatrics (AAP) has recommended intramuscular vitamin K prophylaxis as standard of care since 1961. Routine prophylaxis is required by law in the United States.
| Route | Dose | Notes |
|---|---|---|
| IM (preferred) | 0.5-1.0 mg phytonadione at birth | Most effective; prevents both early and late VKDB |
| Oral | Multiple-dose regimens | Less effective than IM for preventing late VKDB; used in countries/families where IM refused |
IM vitamin K is more effective than oral administration for preventing late hemorrhagic disease. - Textbook of Family Medicine, 9e
There has been an increasing rate of parental refusal in the past decade - an important public health concern leading to recurrence of late VKDB cases. - Tintinalli's Emergency Medicine; see also the Neonatologists and vitamin K hesitancy review (2023)
Key Points for Clinical Practice
- VKDB is the modern preferred term for hemorrhagic disease of the newborn
- All infants are born functionally vitamin K deficient; formula-fed babies rarely develop VKDB because formulas are supplemented
- Breastfed infants without prophylaxis are at highest risk - especially for late VKDB with ICH
- The classic lab pattern: prolonged PT + prolonged aPTT + normal TT + normal platelets + normal fibrinogen
- Menadione (synthetic vitamin K3) is no longer used - it caused hemolytic anemia and jaundice in infants
- Intracranial hemorrhage in a neonate with a coagulopathy should always prompt evaluation and treatment for VKDB
Sources: Bradley and Daroff's Neurology in Clinical Practice | Tintinalli's Emergency Medicine | Goodman & Gilman's Pharmacological Basis of Therapeutics | Tietz Textbook of Laboratory Medicine, 7th Ed | Textbook of Family Medicine, 9e | Lippincott Illustrated Reviews: Biochemistry, 8th Ed
This is a shared conversation. Sign in to Orris to start your own chat.